Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 41.54
- Piotroski Score 1.00
- Grade Buy
- Symbol (LENZ)
- Company LENZ Therapeutics, Inc.
- Price $23.68
- Changes Percentage (-1.5%)
- Change -$0.36
- Day Low $22.73
- Day High $25.41
- Year High $25.77
LENZ Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing aceclidine-based eye drop to enhance vision in patients diagnosed with presbyopia. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.
- Last Earnings N/A
- Ex-Dividend for 5/16 Dividend 03/22/2024
- Dividend Payable N/A
- Today N/A
- Next Earnings (Estimated) 11/07/2024
- Fiscal Year End N/A
- Average Stock Price Target $34.00
- High Stock Price Target $36.00
- Low Stock Price Target $32.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $0.00
- Trailing P/E Ratio N/A
- Forward P/E Ratio N/A
- P/E Growth N/A
- Net Income $-124,651,000
Income Statement
Quarterly
Annual
Latest News of LENZ
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Insider Sale: CFO Steve Valenzuela Sells Shares of Alarm.com Holdings Inc (ALRM)
Alarm.com Holdings Inc offers cloud-based security solutions for connected properties across residential, commercial, and enterprise segments. Recent insider sales, including Steve Valenzuela's 26,614...
By Yahoo! Finance | 1 month ago -
We Think LENZ Therapeutics (NASDAQ:LENZ) Can Afford To Drive Business Growth
While some unprofitable businesses like Salesforce.com have seen success, others like Pets.com have failed. LENZ Therapeutics (NASDAQ:LENZ) had a cash runway of about 3.0 years in March 2024, with ana...
By Yahoo! Finance | 3 months ago